Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева; 2Ставропольский государственный медицинский университет Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310
Список исп. литературыСкрыть список 1. Абрамов В.А., Денисов Е.М., Ряполова Т.Л. Атипичный антипсихотик Солиан: результаты исследования STAR. Нейро news. 2008; 2: 78–82. / Abramov V.A., Denisov E.M., Riapolova T.L. Atipichnyi antipsikhotik Solian: rezul'taty issledovaniia STAR. Neiro news. 2008; 2: 78–82. [in Russian] 2. Абрамова Л.И., Дмитренко И.В., Михайлова В.А. и др. Амисуль-прид (Солиан): купирующая и поддерживающая терапия больных шизофренией. Психиатрия и психофармакотерапия. 2010; 12 (1): 55–64. / Abramova L.I., Dmitriyenko I.V., Mikhailova V.A. et al. Amisulpride (Solian): therapy of patients with schizophrenia. Psychiatry and Psychopharmacotherapy. 2010; 12 (1): 55 –64. [in Russian] 3. Аведисова А.С., Ахапкин Р.В. Антинегативное действие солиана при терапии больных шизофренией. Соц. и клин. психиатрия. 2009; c. 82–8. / Avedisova A.S., Akhapkin R.V. Antinegativnoe deistvie soliana pri terapii bol'nykh shizofreniei. Sots. i klin. psikhiatriia. 2009; c. 82–8. [in Russian] 4. Аведисова А.С., Ястребов Д.В. Амисульприд (Солиан): наиболее атипичный из атипичных нейролептиков. Фарматека. 2006; 2 (6): 40–50. / Avedisova A.S., Iastrebov D.V. Amisul'prid (Solian): naibolee atipichnyi iz atipichnykh neiroleptikov. Farmateka. 2006; 2 (6): 40–50. [in Russian] 5. Аведисова А.С., Ахапкин Р.В. Купирующая и поддерживающая терапия шизофрении Солианом (Амисульпридом). Соц. и клин. психиатрия. 2009; 4: 65–73. / Avedisova A.S., Akhapkin R.V. Kupiruiushchaia i podderzhivaiushchaia terapiia shizofrenii Solianom (Amisul'pridom). Sots. i klin. psikhiatriia. 2009; 4: 65–73. [in Russian] 6. Белокурова Е.А., Дороднова А.С., Мовина Л.Г. Опыт применения амисульприда (солиана) у больных с первыми психотическими эпизодами шизофрении на ранних этапах шизофренического процесса. Соц. и клин. психиатрия. 2005; 2: 79–81. / Belokurova E.A., Dorodnova A.S., Movina L.G. Opyt primeneniia amisul'prida (soliana) u bol'nykh s pervymi psikhoticheskimi epizodami shizofrenii na rannikh etapakh shizofrenicheskogo protsessa. Sots. i klin. psikhiatriia. 2005; 2: 79–81. [in Russian] 7. Васюк В.К., Шейфер М.С., Носенко Н.Ф., Васюк Л.В. Сравнительная эффективность и переносимость амисульприда и рисперидона в терапии острых состояний при шизофрении. Психиатрия и психофармакотерапия. 2006; 8 (3): 29–32. / Vasiuk V.K., Sheifer M.S., Nosenko N.F., Vasiuk L.V. Sravnitel'naia effektivnost' i perenosimost' amisul'prida i risperidona v terapii ostrykh sostoianii pri shizofrenii. Psychiatry and Psychopharmacotherapy. 2006; 8 (3): 29–32. [in Russian] 8. Вельтищев Д.Ю. Многоликий Эглонил. РМЖ. 2001; 9 (25): 1–10. / Vel'tishchev D.Iu. Mnogolikii Eglonil. RMZh. 2001; 9 (25): 1–10. [in Russian] 9. Ворсина О.П., Крамынин П.Б., Павлова О.Н., Сенько Е.В. Опыт применения амисульприда (солиан) в терапии шизофрении и шизоаффективных расстройств. Психиатрия и психофармакотерапия. 2005; 7 (5): 268–70. / Vorsina O.P., Kramynin P.B., Pavlova O.N., Sen'ko E.V. Opyt primeneniia amisul'prida (solian) v terapii shizofrenii i shizoaffektivnykh rasstroistv. Psychiatry and Psychopharmacotherapy. 2005; 7 (5): 268–70. [in Russian] 10. Григорьева Е.А., Рицков А.С. Особенности действия атипичного нейролептика амисульприда. Журн. неврологии и психиатрии им. С.С.Корсакова. 2004; 6: 59–64. / Grigor'eva E.A., Ritskov A.S. Osobennosti deistviia atipichnogo neiroleptika amisul'prida. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2004; 6: 59–64. [in Russian] 11. Григорьева Е.А., Лобанова И.В. Опыт совместного применения стимулотона (сертралина) и солиана (амисульпирида) при терапии депрессий в рамках рекуррентного депрессивного расстройства. Соц. и клин. психиатрия. 2006; 2: 62–7. / Grigor'eva E.A., Lobanova I.V. Opyt sovmestnogo primeneniia stimulotona (sertralina) i soliana (amisul'pirida) pri terapii depressii v ramkakh rekurrentnogo depressivnogo rasstroistva. Sots. i klin. psikhiatriia. 2006; 2: 62–7. [in Russian] 12. Гуревич Л.Г., Былим И.А. Опыт применения солиана в Ставропольской краевой клинической психиатрической больнице. Обозрение психиатрии и мед. психологии. 2005; 3: 30–2. / Gurevich L.G., Bylim I.A. Opyt primeneniia soliana v Stavropol'skoi kraevoi klinicheskoi psikhiatricheskoi bol'nitse. Obozrenie psikhiatrii i med. psikhologii. 2005; 3: 30–2. [in Russian] 13. Гусева Л.И., Астахова Л.В., Анопа Г.Д. и др. К вопросу о профиле безопасности препарата «Амисульприд». Психиатрия и психофармакотерапия. 2006; 8 (4): 35–6. / Guseva L.I., Astakhova L.V., Anopa G.D. i dr. K voprosu o profile bezopasnosti preparata «Amisul'prid». Psychiatry and Psychopharmacotherapy. 2006; 8 (4): 35–6. [in Russian] 14. Коротаева Ж.Е. Опыт применения амисульприда (солиана) в терапии шизофрении и шизотипических расстройств у детей и подростков. Обозрение психиатрии и мед. психологии. 2006; 3: 24–6. / Korotaeva Zh.E. Opyt primeneniia amisul'prida (soliana) v terapii shizofrenii i shizotipicheskikh rasstroistv u detei i podrostkov. Obozrenie psikhiatrii i med. psikhologii. 2006; 3: 24–6. [in Russian] 15. Кузенкова Н.Н. Опыт применения амисульприда (солиан) в терапии психических расстройств у детей и подростков. Психиатрия и психофармакотерапия. 2005; 7 (6): 338–40. / Kuzenkova N.N. Opyt primeneniia amisul'prida (solian) v terapii psikhicheskikh rasstroistv u detei i podrostkov. Psychiatry and Psychopharmacotherapy. 2005; 7 (6): 338–40. [in Russian] 16. Медведев В.Э. Атипичный антипсихотик амисульприд (Лимипранил): возможности и перспективы. Соц. и клин. психиатрия. 2010; 4: 125–34. / Medvedev V.E. Atipichnyi antipsikhotik amisul'prid (Limipranil): vozmozhnosti i perspektivy. Sots. i klin. psikhiatriia. 2010; 4: 125–34. [in Russian] 17. Мортимер А.М. Амисульприд в лечении шизофрении: новые данные. Соц. и клин. психиатрия. 2011; 4: 72–6. / Mortimer A.M. Amisul'prid v lechenii shizofrenii: novye dannye. Sots. i klin. psikhiatriia. 2011; 4: 72–6. [in Russian] 18. Дж.И.Сильвеира да Мота Нето, В.Кисслинг, К.Комосса и др. Амисульприд в сравнении с другими атипичными антипсихотиками при лечении шизофрении. Соц. и клин. психиатрия. 2011; 1: 91–3. / Dzh.I.Sil'veira da Mota Neto, V.Kissling, K.Komossa i dr. Amisul'prid v sravnenii s drugimi atipichnymi antipsikhotikami pri lechenii shizofrenii. Sots. i klin. psikhiatriia. 2011; 1: 91–3. [in Russian] 19. Снедков Е.В. Атипичные антипсихотики: поиск решения старых и новых проблем. Психиатрия и психофармакотерапия. 2006; 8 (4): 45–50. / Snedkov E.V. Atipichnye antipsikhotiki: poisk resheniia starykh i novykh problem. Psychiatry and Psychopharmacotherapy. 2006; 8 (4): 45–50. [in Russian] 20. Тарасевич Л.А. Опыт применения амисульприда у больных шизофренией в условиях принудительного лечения. Обозрение психиатрии и мед. психологии. 2005; 4: 31–4. / Tarasevich L.A. Opyt primeneniia amisul'prida u bol'nykh shizofreniei v usloviiakh prinuditel'nogo lecheniia. Obozrenie psikhiatrii i med. psikhologii. 2005; 4: 31–4. [in Russian] 21. Четвериков Д.В., Мазурова Л.Э. Амисульприд (солиан) в лечении биполярного аффективного расстройства, коморбидного с героиновой аддикцией (клиническое наблюдение). Обозрение психиатрии и мед. психологии. 2005; 2: 30–1. / Chetverikov D.V., Mazurova L.E. Amisul'prid (solian) v lechenii bipoliarnogo affektivnogo rasstroistva, komorbidnogo s geroinovoi addiktsiei (klinicheskoe nabliudenie). Obozrenie psikhiatrii i med. psikhologii. 2005; 2: 30–1. [in Russian] 22. Abbas AI, Hedlund PB, Huang XP et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009; 205 (1): 119–28. 23. Agarwal SM, Rao NP, Venkatasubramanian G et al. Successful treatment of atypical depression with amisulpride: a case report. Asian J Psychiatr 2012; 5 (4): 362. 24. Arlt J, Lambert M, Naber D. Амисульприд как эффективное и безопасное средство, применяемое в качестве препарата выбора при длительном лечении больных шизофренией (расширенный реферат). Психиатрия и психофармакотерапия. 2004; 6 (5): 253–7. / Arlt J, Lambert M, Naber D. Amisul'prid kak effektivnoe i bezopasnoe sredstvo, primeniaemoe v kachestve preparata vybora pri dlitel'nom lechenii bol'nykh shizofreniei (rasshirennyi referat). Psychiatry and Psychopharmacotherapy. 2004; 6 (5): 253–7. 25. Artigas F. Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol 2015; 25 (5): 657–70. 26. Ben Maïz H, Kheder A, Kouki F et al. Pheochromocytoma with compression of renal vasculary pedicle and hypoplastic kidney: interest of sulpiride and propranolol tests (author's transl). [Article in French]. Ann Med Interne (Paris) 1982; 133 (3): 164–8. 27. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs 2012; 26 (2): 135–53. 28. Cesarani A, Alpini D, Monti B et al. The treatment of acute vertigo. Neurol Sci 2004; 25 (1): 26–30. 29. Cordonnier L, Sanchez M, Roques BP et al. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment. Neuroscience 2005; 135 (1): 1–10. 30. Eisenhofer G, Rivers G, Rosas AL et al. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf 2007; 30 (11): 1031–62. 31. Gao K, Muzina D, Gajwani P et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67 (9): 1327–40. 32. Garay RP, Samalin L, Hameg A, Llorca PM. Investigational drugs for anxiety in patients with schizophrenia. Exp Opin Investig Drugs 2015; 24 (4): 507–17. 33. Gómez-Lázaro E, Garmendia L, Beitia G et al. Effects of a putative antidepressant with a rapid onset of action in defeated mice with different coping strategies. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38 (2): 317–27. 34. Guillemot J, Compagnon P, Cartier D et al. Metoclopramide stimulates catecholamine – and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer 2009; 16 (1): 281–90. 35. Hardoy MC, Carta MG. Strategy to Accelerate or Augment the Antidepressant Response and for An Early Onset of SSRI Activity. Adjunctive Amisulpride to Fluvoxamine in Major Depressive Disorder. Clin Pract Epidemiol Ment Health 2010; 6: 1–3. 36. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009; 206 (3): 345–54. 37. Henry A, Charpiat B, Vial T et al. Pheochromocytoma unmasked by amisulpride and tiapride. Ann Pharmacother 2005; 39 (5): 970–2. 38. Hofer A, Rettenbacher MA, Edlinger M et al. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine. Pharmacopsychiatry 2007; 40 (1): 1–8. 39. Hołuj M, Popik P, Nikiforuk A. Improvement of ketamine-induced social withdrawal in rats: the role of 5-HT7 receptors. Behav Pharmacol 2015; 26 (8 Spec No): 766–75. 40. Kim SW, Shin IS, Kim JM. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31 (7): 1504–9. 41. Kochanowski J. Prophylactic treatment of migraine. [Article in Polish]. Neurol Neurochir Pol 1999; 32 (Suppl. 6): 75–80. 42. Komossa K, Depping AM, Gaudchau A et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010; 12: CD008121. 43. Kranke P, Eberhart L, Motsch J et al. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. Br J Anaesth 2013; 111 (6): 938–45. 44. Kreinin A, Miodownik C, Sokolik S. Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. World J Biol Psychiatry 2011; 12 (8): 620–6. 45. Kriston L, von Wolff A, Westphal A et al. Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis. Depress Anxiety 2014; 31 (8): 621–30. 46. Kulkarni RR. Low-dose Amisulpride for Debilitating Clozapine-induced Sialorrhea: Case Series and Review of Literature. Indian J Psychol Med 2015; 37 (4): 446–8. 47. Kumar S, Chaudhury S. Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study. Ind Psychiatry J 2014; 23 (1): 27–35. 48. Maina G, Vitalucci A, Gandolfo S et al. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002; 63 (1): 38–43. 49. Maitre M, Ratomponirina C, Gobaille S et al. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics. Eur J Pharmacol 1994; 256 (2): 211–4. 50. Mendez-David I, David DJ, Darcet F et al. Rapid anxiolytic effects of a 5-HT₄ receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology 2014; 39 (6): 1366–78. 51. Montemurro D, Rossi GP. Veralipride-induced acute coronary syndrome unmasking a non-secreting pheochromocytoma. J Endocrinol Invest 2006; 29 (7): 650–2. 52. Montgomery SA. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol 2002; 17 (Suppl. 4): S9–15; discussion S16–17. 53. Munro J, Matthiasson P, Osborne S. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110 (4): 292–8. 54. Nikiforuk A, Kos T, Fijał K et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One 2013; 8 (6): e66695. 55. Nikiforuk A, Popik P. Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors. Behav Brain Res 2013; 248: 136–40. 56. Nunes EA, Freire RC, Dos Reis M et al. Sulpiride and refractory panic disorder. Psychopharmacology (Berl) 2012; 223 (2): 247–9. 57. Oishi S, Shimada T, Sato T. Case of intrathoracic pheochromocytoma occurring 9 years after resection of intraabdominal paraaortic pheochromocytoma: effect of metoclopramide and sulpiride on catecholamine secretion in vitro. [Article in Japanese]. Nihon Naibunpi Gakkai Zasshi 1983; 59 (10): 1608–19. 58. Pardini M, Guida S, Primavera A et al. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. Eur Neuropsychopharmacol 2011; 21 (3): 282–6. 59. Perrot L, Chavrier B, Berthezène F, Mornex R. Place of sulpirid test in the diagnosis of pheochromocytoma (author's transl). [Article in French]. Ann Endocrinol (Paris) 1979; 40 (6): 565–6. 60. Praharaj SK, Ray P, Gandotra S. Amisulpride improved debilitating clozapine-induced sialorrhea. Am J Ther 2011; 18 (3): e84–85. 61. Racagni G, Canonico PL, Ravizza L et al. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 2004; 50 (2): 134–43. 62. Rajagopal L, Massey BW, Huang M et al. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 2014; 20 (31): 5104–14. 63. Ratomponirina C, Gobaille S, Hodé Y et al. Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells. Eur J Pharmacol 1998; 346 (2–3): 331–7. 64. Rico-Villademoros F, Calandre EP, Slim M. Current status of atypical antipsychotics for the treatment of fibromyalgia. Drugs Today (Barc) 2014; 50 (6): 435–44. 65. Rico-Villademoros F, Rodriguez-Lopez CM, Morillas-Arques P et al. Amisulpride in the treatment of fibromyalgia: an uncontrolled study. Clin Rheumatol 2012; 31 (9): 1371–5. 66. Rodriguez-Cerdeira C, Sanchez-Blanco E. Treatment of burning mouth syndrome with amisulpride. J Clin Med Res 2012; 4 (3): 167–71. 67. Roesch-Ely D, Göhring K, Gruschka P et al. Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. Pharmacopsychiatry 2006; 39 (3): 115–6. 68. Ruhrmann S, Bechdolf A, Kühn KU et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007; 51: 88–95. 69. Rybakowski JK, Vansteelandt K, Szafranski T et al. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol 2012; 22 (12): 875–82. 70. Sabriá M, Cuevas J, Tallada N et al. Pheochromocytoma and sudden death (author's transl). [Article in Spanish]. Med Clin (Barc) 1979; 73 (9): 37. 71. Serra J. Levosulpiride in the management of functional dyspepsia and delayed gastric emptying. Gastroenterol Hepatol 2010; 33 (8): 586–90. 72. Siniachkin MS, Veĭn AM, Voznesenskaia TG et al. [Sulpiride in the prophylactic treatment of migraine]. Zh Nevrol Psikhiatr Im S S Korsakova 1997; 97 (11): 28–32. 73. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Ed. Cambridge University Press, 2013; p. 227–8. 74. Takács R, Iványi Z, Ungvari GS, Gazdag G. Safety of the electroconvulsive therapy and amisulpride combination. Psychiatr Danub 2013; 25 (1): 76–9. 75. Tonini M, De Giorgio R, Spelta V et al. 5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract. Dig Liver Dis 2003; 35 (4): 244–50. 76. Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006; 21 (8): 523–30. 77. Vidal R, Castro E, Pilar-Cuéllar F et al. Serotonin 5-HT4 receptors: A new strategy for developing fast acting antidepressants? Curr Pharm Des 2014; 20 (23): 3751–62. 78. Vil'yanov VB, Kremenitskaya SA, Solov'eva NV. The efficacy of sulpiride in patients with anxiety disorders depending on the serum serotonin concentrations. [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova 2015; 115 (10): 62–5. 79. Weizman T, Pick CG, Backer MM et al. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms. Eur J Pharmacol 2003; 478 (2–3): 155–9. 80. Werner FM, Coveñas R. Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease. Curr Pharm Des 2016. 81. Zanardi R, Smeraldi E. A double-lind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006; 16 (4): 281–7.